AGC Biologics aims to become ‘safe harbor’ for manufacturing clients as new CEO takes the reins
AGC Biologics, led by new CEO Alberto Santagostino, plans to scale and strengthen its reputation as a customer-friendly, expert-driven CDMO.
Building on AGC Biologics’ extensive 30-year track record, which includes 25 commercial products and 250 clients across 400 different projects, Santagostino plans to differentiate the company through being more approachable than its CDMO peers. Additionally, he aims to further leverage AGC’s strong capabilities in cell and microbial manufacturing.
Headquartered in Seattle, AGC Biologics is set to expand its global manufacturing footprint under Santagostino’s new vision.